Table 3. Clinical characteristics for patients with or without omentectomy.
| Clinical patient characteristics | No omentectomy n=121 (21.6%) | Omentectomy n=438 (78.4%) | P-value |
|---|---|---|---|
|
Age at first diagnosis | |||
| Median, years | 53 | 48 | 0.192a |
| Range |
(16–92) |
(14–86) |
|
| FIGO stage | <0.001b | ||
| IA/B | 81 (67.0%) | 198 (45.2%) | |
| IC | 23 (19.0%) | 111 (25.3%) | |
| IIA-C | 14 (11.6%) | 51 (11.7%) | |
| IIIA-C | 3 (2.5%) | 78 (17.8%) | |
| Surgical approach in primary and re-staging surgery | <0.001b | ||
| Laparoscopy | 32 (26.4%) | 43 (9.8%) | |
| Laparotomy |
89 (73.6%) |
395 (90.2%) |
|
|
Surgical procedures in primary and re-staging surgeryc | |||
| Bilateral salpingo-oophorectomy | 81 (66.9%) | 369 (84.2%) | <0.001b |
| Unilateral salpingo-oophorectomy | 29 (24.0%) | 106 (24.2%) | 0.958b |
| Cystectomy | 27 (22.3%) | 76 (17.4%) | 0.221b |
| Hysterectomy | 62 (51.2%) | 336 (76.7%) | <0.001b |
| Peritoneal biopsies | 30 (24.8%) | 344 (78.5%) | <0.001b |
| Cytology | 56 (46.3%) | 326 (74.4%) | <0.001b |
| Appendectomy | 14 (11.6%) | 151 (34.5%) | <0.001b |
| Pelvic LND/LN biopsies | 15 (12.4%) | 103 (23.5%) | 0.005b |
| Para-aortic LND/LN biopsies |
7 (5.8%) |
70 (16.0%) |
0.002b |
| Peritoneal implants in primary or re-staging surgery |
|
|
<0.001b |
| None | 107 (88.4%) | 321 (73.3%) | |
| Non-invasive | 12 (9.9%) | 98 (22.4%) | |
| Invasive |
2 (1.7%) |
19 (4.3%) |
|
| Surgical cytoreduction |
|
|
0.530b |
| Complete | 109 (90.1%) | 408 (93.2%) | |
| Incomplete | 2 (1.7%) | 6 (1.4%) | |
| Unknown |
10 (8.3%) |
24 (5.5%) |
|
| Staging quality after primary and re-staging surgery |
|
|
<0.001b |
| Adequate | 0 (0.0%) | 278 (63.5%) | |
| Inadequate |
121 (100.0%) |
160 (36.5%) |
|
| Fertility-sparing surgery |
|
|
<0.001b |
| Yes | 40 (33.1%) | 70 (16.0%) | |
| No |
81 (66.9%) |
368 (84.0%) |
|
| Up-staging after re-staging surgery |
|
|
0.026b |
| Yes | 2 (1.7%) | 27 (6.2%) | |
| No |
119 (98.3%) |
411 (93.8%) |
|
| Recurrent disease |
|
|
0.029b |
| Yes | 18 (14.9%) | 35 (8.0%) | |
| Borderline tumour | 14/18 (77.8%) | 26/35 (74.3%) | |
| High grade carcinoma | 1/18 (5.6%) | 3/35 (8.6%) | |
| Low grade carcinoma | 2/18 (11.1%) | 6/35 (17.1%) | |
| Unknown | 1/18 (5.6%) | 0/35 (0.0%) | |
| No |
103 (85.1%) |
403 (92.0%) |
|
|
Site of recurrent diseasec | |||
| Ovarian tissue | 8/18 (44.4%) | 18/35 (51.4%) | |
| Ipsilateral | 4/18 (22.2%) | 5/35 (14.3%) | |
| Contralateral | 4/18 (22.2%) | 16/35 (45.7%) | |
| Peritoneum | 5/18 (27.8%) | 23/35 (65.7%) | |
| Omentum | 1/18 (5.6%) | 0/35 (0.0%) | |
| Other | 0/18 (0.0%) | 2/35 (5.8%) | |
| Unknown |
5/18 (27.8%) |
5/35 (14.3%) |
|
| 5-year progression-free survival |
79.9% |
89.3% |
0.004d |
| 5-year disease-specific survival | 98.8% | 99.7% | 0.893d |
Abbreviations: FIGO=International Federation of Gynecology and Obstetrics; LND=lymph node dissection; LN=lymph node.
a
Student's t-test.
b
Chi2-test.
c
multiple entries possible.
d
log-rank test.